HLA-DR Expression and Colorectal Cancer Prognosis
Author Information
Author(s): T Løvig, S N Andersen, L Thorstensen, C B Diep, G I Meling, R A Lothe, T O Rognum
Primary Institution: Institute of Forensic Medicine, The National Hospital, University of Oslo
Hypothesis
Is strong HLA-DR expression in colorectal carcinomas associated with better patient survival?
Conclusion
Patients with strong HLA-DR expression in their colorectal tumors have improved survival compared to those without HLA-DR expression.
Supporting Evidence
- 16% of tumors showed strong HLA-DR expression.
- Patients with strong HLA-DR staining had improved survival compared to those with no HLA-DR expression.
- Strong HLA-DR expression was significantly associated with high levels of microsatellite instability.
Takeaway
If a patient has a certain marker called HLA-DR in their colorectal cancer, they are more likely to live longer than those who don't have it.
Methodology
The study analyzed HLA-DR expression in 357 colorectal carcinomas using immunohistochemistry and assessed its association with patient survival.
Limitations
The study did not include information on Amsterdam criteria for the first series of tumors.
Participant Demographics
Median age at diagnosis was 67 years for males and 69 years for females.
Statistical Information
P-Value
P<0.001
Confidence Interval
95% CI: 0.20–0.96
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website